Published in Obesity and Diabetes Week, December 12th, 2005
"Few large randomized controlled trials have assessed the value of adding insulin to an oral antidiabetic drug regimen. This trial compared the efficacy and safety of biphasic insulin aspart 30/70 (BIAsp 30) plus pioglitazone (n=93), glibenclamide (glyburide) plus pioglitazone (n 91), or BIAsp 30 monotherapy (n=97)," scientists in Israel report.
I. Raz and colleagues working with the Hadassah Hebrew University Hospital explained, "This 18-week, multinational, multicenter, randomized, open-label, parallel-group trial involved 281 patients with type 2 diabetes (60%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week